N/A
Manufactured by Janssen Products, LP
4,147 FDA adverse event reports analyzed
Last updated: 2026-04-15
RILPIVIRINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Janssen Products, LP. The most commonly reported adverse reactions for RILPIVIRINE HYDROCHLORIDE include ANXIETY, PAIN, EMOTIONAL DISTRESS, ANHEDONIA, CHRONIC KIDNEY DISEASE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RILPIVIRINE HYDROCHLORIDE.
Out of 1,884 classified reports for RILPIVIRINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 4,147 FDA FAERS reports that mention RILPIVIRINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ANXIETY, PAIN, EMOTIONAL DISTRESS, ANHEDONIA, CHRONIC KIDNEY DISEASE, RENAL FAILURE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Janssen Products, LP in connection with RILPIVIRINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.